Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z
Галектин-3: одна молекула для алфавита заболеваний — от А до Я
2018-01-26
SCID: 54.1/gxd5dq6g
Discuss with AI
Galectin-3cancer and fibrosisdiagnostic biomarkerprognostic biomarkertherapeutic target
Figures from the paper
Abstract (AI)
Galectin-3 (Gal-3) regulates basic cellular functions such as cell-cell and cell-matrix interactions, growth, proliferation, differentiation, and inflammation. It is not surprising, therefore, that this protein is involved in the pathogenesis of many relevant human diseases, including cancer, fibrosis, chronic inflammation and scarring affecting many different tissues. The papers published in the literature have progressively increased in number during the last decades, testifying the great interest given to this protein by numerous researchers involved in many different clinical contexts. Considering the crucial role exerted by Gal-3 in many different clinical conditions, Gal-3 is emerging as a new diagnostic, prognostic biomarker and as a new promising therapeutic target. The current review aims to extensively examine the studies published so far on the role of Gal-3 in all the clinical conditions and diseases, listed in alphabetical order, where it was analyzed.
Key Findings
1
Galectin-3 is emerging as a diagnostic and prognostic biomarker and a promising therapeutic target.
2
Galectin-3 is implicated in the pathogenesis of cancer, fibrosis, chronic inflammation, and tissue scarring across multiple organs.
3
Galectin-3 regulates cell-cell and cell-matrix interactions, growth, proliferation, differentiation, and inflammation.
4
The expanding literature on Galectin-3 reflects broad research interest across diverse clinical contexts and diseases.
5
The review comprehensively examines Galectin-3 across clinical conditions and diseases, organized alphabetically from A to Z.
Research Object
Galectin-3 (Gal-3) in human diseases and clinical conditions
Research Subject
The role, diagnostic and prognostic biomarker potential, and therapeutic-target relevance of Gal-3 across diseases, including cancer, fibrosis, chronic inflammation, and scarring
Publication Details
Publication Date
2018-01-26
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest